Enveric Biosciences Inc - Asset Resilience Ratio
Enveric Biosciences Inc (ENVB) has an Asset Resilience Ratio of 0.75% as of March 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Enveric Biosciences Inc (ENVB) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2016)
This chart shows how Enveric Biosciences Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Enveric Biosciences Inc.
Liquid Assets Composition Over Time
This chart breaks down Enveric Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read ENVB total debt and obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $227.34K | 0.75% |
| Total Liquid Assets | $227.34K | 0.75% |
Asset Resilience Insights
- Limited Liquidity: Enveric Biosciences Inc maintains only 0.75% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Enveric Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Enveric Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Enveric Biosciences Inc (2007–2016)
The table below shows the annual Asset Resilience Ratio data for Enveric Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2016-12-31 | 0.21% | $82.91K | $39.51 Million | -0.39pp |
| 2015-12-31 | 0.60% | $82.91K | $13.83 Million | -61.71pp |
| 2007-12-31 | 62.30% | $1.00 Million | $1.61 Million | -- |
About Enveric Biosciences Inc
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage fo… Read more